Urinary tract infections (UTIs) are common in children and are associated with significant short- and long-term morbidity. They have a high recurrence rate and are associated with anatomic and functional abnormalities. The decision to test for UTI is based on risk factors and the child’s age. Urinalysis is valuable to rule out UTI and to help decide when to start antibiotics; however, urine culture is needed for definitive diagnosis. Urine specimens collected via perineal bagging should not be used for culture because of high false-positive rates. Diagnosis of UTI requires pyuria and bacterial growth in the urine culture. Prompt treatment of UTIs reduces renal scarring. Antibiotic selection should be based on local sensitivity patterns and adjusted once culture results are available. In most cases, oral antibiotics are as effective as intravenous agents. When intravenous antibiotics are used, early transition to an oral regimen is as effective as longer intravenous courses. Kidney and bladder ultrasonography is helpful to identify acute complications and anatomic abnormalities. Voiding cystourethrogram is indicated when ultrasound findings are abnormal and in cases of recurrent febrile UTIs. The use of antibiotic prophylaxis for recurrent UTIs is controversial. Identification and treatment of bowel and bladder dysfunction can prevent UTI recurrence. (Am Fam Physician. 2020;102(5):278-285. Copyright © 2020 American Academy of Family Physicians.)

**Urinary tract infections** (UTIs) are common in children and are associated with significant morbidity. Up to 7% of girls and 2% of boys have had a UTI by six years of age. The recurrence rate is 30%. One in six febrile neonates has a UTI, and it is the most common serious bacterial infection in children younger than three months. Short-term complications may include sepsis, renal abscess, and acute kidney injury; potential long-term sequelae include renal scarring, recurrent infection, impaired renal function, hypertension, end-stage renal disease, and preeclampsia. Prophylactic antibiotics are commonly prescribed, but their use has questionable benefit and contributes to microbial resistance.

**Which Children Should Be Tested for a UTI?**

A urine sample should be obtained for testing before antibiotic therapy is initiated in clinically unstable children who do not have a clear source of infection. In other children, age and clinical findings can be used to determine the need for testing. The physician’s overall clinical impression for UTI often misses the diagnosis.

**EVIDENCE SUMMARY**

Because antibiotics can rapidly sterilize urine and thereby limit the ability to diagnose UTI, a urine sample should be obtained using an age-appropriate method before antibiotic therapy is initiated. For children who do not require urgent antibiotic therapy, clinical characteristics can identify those at higher risk of UTI who require testing (Figure 1).

Urine testing is indicated for all acutely ill infants (both febrile and afebrile) who are younger than three months. For febrile children two to 24 months of age, the 2011 American Academy of Family Physicians guidelines recommend urine testing with negative results followed by repeat testing if symptoms persist or recur. For children older than 24 months, urine testing is recommended if symptoms persist or recur, or if clinical suspicion is high.

**CME** This clinical content conforms to AAFP criteria for CME. See CME Quiz on page 287.

Author disclosure: No relevant financial affiliations.

Patient information: A handout on this topic, written by the authors of this article, is available at https://www.aafp.org/afp/2020/0901/p278-s1.html.
of Pediatrics (AAP) guideline recommended basing testing decisions on risk factors and absence of alternative sources of infection. However, this guideline was retired in 2021 because of improper use of race as a risk factor and potential for missed diagnoses in Black and non-White children. The UTICalc, a tool developed by the University of Pittsburgh (https://uticalc.pitt.edu), uses similar risk factors (excluding race) to estimate the risk of UTI in febrile children two to 23 months of age. Testing is recommended when the risk is 2% or greater.

Two observational studies in the United Kingdom raise concern for UTI in unwell but afebrile children. In one study of 597 children younger than five years, absence of fever did not sufficiently rule out UTI. A particularly high rate of UTIs was noted in infants younger than three months (12.5%); thus, the authors recommend that all acutely ill children in this age group be tested regardless of symptoms. A second observational study of 2,740 children younger than five years found that the following clinical findings were associated with an increased risk of UTI: pain or crying with urination, malodorous urine, absence of cough, abdominal tenderness, lack of ear abnormalities, bowel and bladder dysfunction, and urinary tract abnormalities. Lack of fever was not useful for ruling out UTI. This study was limited by underrepresentation of children younger than two years, who comprised only 6.5% of the study population.

**FIGURE 1**

Algorithm for determining when to test for UTIs in children.

UTI = urinary tract infection.

*—If urinalysis shows signs of infection (leukocyte esterase or nitrates on dipstick urinalysis; white blood cells or bacteria on microscopy), urine should be cultured from an appropriately collected sample, and empiric antibiotics should be started.

†—Go to https://uticalc.pitt.edu.

‡—Risk factors include younger age, girl or uncircumcised boy, history of UTI, severe illness, pain or crying with urination, malodorous urine, absence of cough, abdominal tenderness, lack of ear abnormalities, bowel and bladder dysfunction, and urinary tract abnormalities.

§—Signs and symptoms of UTI include urinary frequency, dysuria, abdominal pain/tenderness, back pain, and new-onset incontinence. Other factors that increase risk include history of UTI, severe illness, malodorous urine, absence of cough, lack of ear abnormalities, bowel and bladder dysfunction, and urinary tract abnormalities.

**BEST PRACTICES IN UROLOGY**

**Recommendations from the Choosing Wisely Campaign**

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Sponsoring organization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avoid ordering follow-up urine cultures after treatment for an uncomplicated urinary tract infection (UTI) in patients that show evidence of clinical resolution of infection.</td>
<td>American Academy of Pediatrics – Section on Nephrology and the American Society of Pediatric Nephrology</td>
</tr>
<tr>
<td>Do not perform voiding cystourethrography routinely for a first febrile UTI in children aged two to 24 months.</td>
<td>American Academy of Family Physicians</td>
</tr>
</tbody>
</table>

Source: For more information on the Choosing Wisely Campaign, see https://www.choosingwisely.org. For supporting citations and to search Choosing Wisely recommendations relevant to primary care, see https://www.aafp.org/afp/recommendations/search.htm.
A study evaluating the diagnostic accuracy of UTI symptoms found that the decision to perform urine testing in verbal children older than 24 months should be based on sex, circumcision status, and symptoms. In girls and uncircumcised boys with urinary frequency, dysuria, abdominal pain or tenderness, back pain, or new-onset incontinence, the probability of UTI is 18% to 30%, and urine testing should be performed. If these symptoms are not present, the probability of UTI is low, and testing is not indicated. The baseline probability of UTI in circumcised boys is less than 1%, and testing is indicated only when at least three of these symptoms are present.

**How Accurate Are Urine Microscopy and Dipstick Testing for UTI Diagnosis?**

Urine microscopy and dipstick testing for leukocyte esterase, nitrites, or blood are useful to rule out UTI. A positive result supports empiric antibiotic treatment, but a urine culture should be obtained to confirm the diagnosis.

**EVIDENCE SUMMARY**

Although individual components of dipstick urinalysis have low sensitivity and specificity for the diagnosis of UTI, their accuracy improves when these components are combined. A positive result for leukocyte esterase has a sensitivity of 83% (range: 67% to 94%) and specificity of 78% (64% to 92%), and a positive result for nitrites has a sensitivity of 53% (15% to 82%) and specificity of 98% (90% to 100%). When both are positive, sensitivity improves to 93% (90% to 100%), but specificity decreases to 72% (58% to 91%). When these results are combined with microscopy findings of bacteria or white blood cells (at least 25 per mL or 5 per high-power field), sensitivity increases to 99.8% (99% to 100%) with a specificity of 70% (60% to 92%). Thus, when all components of dipstick testing and urine microscopy are negative, the negative predictive value is high.

Studies published since the AAP’s 2011 guidelines found similar results. A 2017 retrospective review of 262 children in Ireland found that the sensitivities of nitrites, blood, and leukocyte esterase individually were 54%, 74%, and 86% (95% CIs, 0.46 to 0.62, 0.68 to 0.80, and 0.82 to 0.91, respectively). The presence of at least 100 white blood cells per mL had a sensitivity of 92% (95% CI, 0.89 to 0.95), but when this was combined with a positive dipstick result the sensitivity increased to 97%. Thus, a combination of dipstick urinalysis and microscopy was suggested as more useful for diagnosing UTI.

A review of urine testing methods in infants younger than 60 days found that a positive result for leukocyte esterase, nitrites, or white blood cells had a sensitivity of 94% (95% CI, 91% to 97%) and specificity of 91% (95% CI, 90% to 91%). When dipstick urinalysis and/or microscopy findings are positive, the AAP recommends obtaining a urine culture to confirm the diagnosis of UTI.

**What Are the Diagnostic Criteria for UTIs in Children?**

To diagnose UTI in a symptomatic child, urine testing must show pyuria and the culture must show significant bacterial growth. Urine specimens should be collected using techniques that minimize contamination, such as suprapubic aspiration, bladder catheterization, or midstream clean catch. Perineal bagging is not acceptable when the risk of UTI is high and empiric therapy will be initiated.

**EVIDENCE SUMMARY**

The diagnosis of UTI requires findings of both pyuria (i.e., positive leukocyte esterase on dipstick urinalysis or white blood cells on urine microscopy) and significant bacterial growth on urine culture. The recommended techniques for urine collection and the minimum uropathogen count required for diagnosis vary by guideline (Table 1). The AAP recommends urine collection by suprapubic aspiration or bladder catheterization in febrile infants, and it requires at least 50,000 colony-forming units of uropathogen per mL of urine. The European Society of Pediatric Urology (ESPU) criteria also require pyuria and bacterial growth, but midstream clean catch is acceptable in toilet-trained children, and the uropathogen criteria are lower than the AAP’s.

Urine specimens obtained via perineal bagging have an unacceptably high false-positive culture rate, which the AAP estimates ranges from 88% to 99%. For this reason, bagged specimens are useful only when dipstick urinalysis, microscopy, and culture results are all negative. Thus, these specimens are useful for ruling out UTI, but not for diagnosis.

**What Are the Most Effective Antibiotic Regimens for UTIs in Children?**

Prompt antibiotic treatment is important to reduce the risk of renal scarring in children with UTIs. Initial antibiotic selection is based on local sensitivity patterns and the risk of resistant bacteria. Once available, culture results should be used to adjust the initial antibiotic selection. Pyelonephritis (i.e., febrile UTI) does not necessitate intravenous antibiotics; the route of administration should be based on the severity of illness, presence of renal abnormalities, response to therapy, and the child’s age and ability to take oral medications. When intravenous antibiotics are used, a shorter course with transition to an oral agent is as effective as a longer intravenous regimen. Children with cystitis (i.e., afebrile UTI)
should receive antibiotics for two to four days, whereas those with pyelonephritis should receive a seven- to 14-day course.

EVIDENCE SUMMARY

Figure 2 details the management of UTIs in young children. Early treatment is associated with reduced renal scarring, and delaying treatment beyond 48 hours has deleterious effects. The AAP recommends prompt treatment for UTI and medical evaluation within 48 hours for children with recurrent symptoms.

Table 2 lists antibiotics commonly used to treat UTIs in children. Cochrane reviews have not found evidence to support the use of specific agents in children with lower UTIs or pyelonephritis. Antibiotic selection should be based initially on local sensitivity patterns and the risk of resistant bacteria, then adjusted once culture results are available. Antibiotics that do not reach therapeutic concentrations in the bloodstream (e.g., nitrofurantoin) are not recommended for the treatment of pyelonephritis in children.

A 2014 Cochrane review found that oral antibiotics alone are as effective as a regimen of intravenous followed by oral antibiotics in children with pyelonephritis. It also found that shorter courses (two to four days) of intravenous antibiotics followed by transition to an oral regimen are as effective as longer courses of an intravenous agent. There were not enough data to apply these findings to infants younger than one month or to children with grades III to V vesicoureteral reflux. The ESPU recommends intravenous therapy for infants younger than two months because of increased rates of bacteremia and severe pyelonephritis. A 2019 study found no difference in the rates of recurrent UTI or hospital readmittance in infants younger than 60 days who received short (up to seven days) vs. longer courses of intravenous antibiotics for UTI and bacteremia. Thus, shorter courses of intravenous antibiotics followed by oral therapy can be considered for infants younger than 60 days.

When Should Imaging Be Considered for a Child with a UTI?

Kidney and bladder ultrasonography is indicated for children with atypical UTIs to identify acute complications. Children with pyelonephritis who are 24 months or younger should undergo ultrasonography within six months of the acute infection. Ultrasonography should be performed in children older than 24 months who have recurrent UTIs. Voiding cystourethrography is also indicated for children with recurrent UTIs and for those with abnormal ultrasound findings. Dimercaptosuccinic acid (DMSA) imaging is not part of standard screening in the United States.

EVIDENCE SUMMARY

Imaging can identify acute complications of UTIs and screen for anatomic or physiologic abnormalities that may cause chronic complications. Kidney and bladder ultrasonography can detect complications such as renal abscess or obstruction in children with atypical UTIs (e.g., those with severe illness, infection with non–Escherichia coli organisms, or an unexpected clinical course). Abnormal findings identify children who are at increased risk of renal scarring. When performed routinely in febrile infants with UTIs, ultrasonography identifies almost all abnormalities that require intervention, with the exception of some cases of vesicoureteral reflux. However, this is not a significant limitation because the benefit of antibiotic prophylaxis for this condition is uncertain.

Voiding cystourethrography exposes children to radiation, and its value for detecting vesicoureteral reflux in patients with uncomplicated UTIs is questionable. Therefore, this imaging modality is reserved for children whose ultrasound findings suggest vesicoureteral reflux or obstructive uropathy, and for those with recurrent UTIs. Although British guidelines incorporate DMSA imaging to detect renal parenchymal defects, the AAP recommends against this modality except for research purposes.

What Is the Role of Antibiotic Prophylaxis for Children with UTIs?

Antibiotic prophylaxis has been used to prevent recurrent UTIs and renal scarring. However, its benefit is unclear, and it promotes antimicrobial resistance. Patients most likely to benefit from antibiotic prophylaxis include children with...
UTIs IN CHILDREN

EVIDENCE SUMMARY
Evidence is mixed on the role of antibiotic prophylaxis to prevent recurrent UTIs. A Cochrane review and a systematic review suggest that long-term use of prophylactic antibiotics may reduce UTI recurrence; however, the benefit is small at best.6,7 The Randomized Intervention for Children with Vesico-ureteral Reflux (RIVUR) trial showed that antibiotic prophylaxis reduced recurrent UTIs in children with grades I to IV reflux.8 However, a Cochrane review showed little to no effect on rates of recurrent UTIs.9 There is also conflicting evidence that antibiotic prophylaxis reduces renal scarring in children with recurrent UTIs. A Cochrane review found that antibiotic prophylaxis has little to no effect on the risk of new or progressive renal damage.9 The RIVUR trial also found no difference in renal scarring when antibiotic prophylaxis was used; however, a systematic review and subanalysis of the RIVUR trial showed that antibiotic prophylaxis prevented scarring.7,28 All of these studies show increased antimicrobial resistance when antibiotic prophylaxis is used to prevent recurrent UTIs.6-9 Compared with other prophylactic antibiotics, nitrofurantoin results in less resistance and is more effective, but it has more adverse effects, such as nausea, vomiting, and stomachache.6,7 Rates of recurrent UTIs can be as high as 51% in children with bowel and bladder dysfunction (lower urinary tract symptoms concurrent with constipation) is associated with UTIs, and treatment of this condition can reduce UTI recurrence. Evidence does not support the use of probiotics or cranberries for UTI prophylaxis. A high risk of recurrent UTIs and those most likely to have adverse effects from recurrent UTIs. Nitrofurantoin is the preferred antibiotic for prophylaxis unless adverse effects limit its use. Bowel and bladder dysfunction (lower urinary tract symptoms concurrent with constipation) is associated with UTIs, and treatment of this condition can reduce UTI recurrence. Evidence does not support the use of probiotics or cranberries for UTI prophylaxis.

Algorithm for the management of UTIs in children.

Information from references 2, 10, 11, 20-23.

*Severe illness, elevated creatinine level, poor urine flow, abnormal abdominal examination findings, poor treatment response, or non–*Escherichia* coli infection.
†Renal abscess, obstruction, or anatomic abnormalities.
‡See Table 2 for antibiotic options. Selection is based on local sensitivities and risk of resistant organisms; route of administration is determined by the clinical situation.

**FIGURE 2**
# Antibiotics Commonly Used to Treat Urinary Tract Infections in Children

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Typical dosage*</th>
<th>Maximum dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oral administration</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amoxicillin†</td>
<td>25 to 50 mg per kg per day, divided into 3 doses</td>
<td>500 mg per dose</td>
</tr>
<tr>
<td></td>
<td>Prophylactic dosage: 10 to 15 mg per kg once per day</td>
<td></td>
</tr>
<tr>
<td>Amoxicillin/clavulanate (Augmentin)</td>
<td>Children 2 to 24 months of age: 20 to 40 mg amoxicillin per kg per day, divided into 3 doses</td>
<td>—</td>
</tr>
<tr>
<td>Cefixime (Suprax)</td>
<td>Children 2 months and older: 8 mg per kg once per day</td>
<td>400 mg per dose</td>
</tr>
<tr>
<td>Cefuroxime axetil</td>
<td>Children older than 2 months: 20 to 30 mg per kg per day, divided into 2 doses</td>
<td>500 mg per dose</td>
</tr>
<tr>
<td>Cephalexin (Keflex)‡</td>
<td>Children 2 to 24 months of age: 50 to 100 mg per kg per day, divided into 4 doses</td>
<td>500 mg per dose</td>
</tr>
<tr>
<td></td>
<td>Children older than 24 months: 25 to 50 mg per kg per day, divided into 2 to 4 doses; for severe infections, 50 to 100 mg per kg per day, divided into 2 to 4 doses</td>
<td></td>
</tr>
<tr>
<td>Nitrofurantoin§</td>
<td>5 to 7 mg per kg per day, divided into 4 doses</td>
<td>100 mg per dose</td>
</tr>
<tr>
<td></td>
<td>Prophylactic dosage: 1 to 2 mg per kg at bedtime</td>
<td></td>
</tr>
<tr>
<td>Trimethoprim/sulfamethoxazole†</td>
<td>Children 2 to 24 months of age: 6 mg/30 mg to 12 mg/60 mg per kg per day, divided into 2 doses</td>
<td>160 mg trimethoprim per dose</td>
</tr>
<tr>
<td></td>
<td>Children older than 24 months: 8 mg/40 mg per kg per day, divided into 2 doses</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prophylactic dosage for children 2 months and older: 2 mg/10 mg per kg once per day</td>
<td></td>
</tr>
<tr>
<td><strong>Intravenous administration</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ampicillin</td>
<td>50 to 400 mg per kg per day, divided into 4 doses</td>
<td>12,000 mg per day</td>
</tr>
<tr>
<td>Cefazolin§</td>
<td>25 to 100 mg per kg per day, divided into 3 doses</td>
<td>6,000 mg per day</td>
</tr>
<tr>
<td>Cefepime</td>
<td>Children 2 months and older: 100 mg per kg per day, divided into 2 doses</td>
<td>2,000 mg per dose</td>
</tr>
<tr>
<td>Cefotaxime</td>
<td>Children 2 to 24 months of age: 150 mg per kg per day, divided into 3 or 4 doses</td>
<td>—</td>
</tr>
<tr>
<td>Ceftriaxone</td>
<td>50 mg per kg once per day</td>
<td>2,000 mg per dose</td>
</tr>
<tr>
<td>Gentamicin</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Neutonates 7 days or younger: 4 mg per kg per day</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Neonates/infants 8 to 60 days of age: 5 mg per kg per day</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Infants/children 2 months to 5 years of age: 7.5 mg per kg once per day</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Conventional dosing: 7.5 mg per kg per day, divided into 3 doses</td>
<td></td>
</tr>
</tbody>
</table>

*—Dosages are for treatment unless otherwise noted.
†—High resistance rates in many communities limit use for empiric therapy.
‡—First-generation cephalosporins are preferred by some hospital-specific guidelines for empiric therapy over second- and third-generation agents because of their narrower spectrum of activity, lower cost, and concern about third-generation cephalosporin resistance. Antibiotic choice should be based on local resistance patterns.
§—Should not be used to treat pyelonephritis.
||—Dosing should be adjusted for serum concentrations to avoid toxicity.

Information from references 5 and 24-26.
SORT: KEY RECOMMENDATIONS FOR PRACTICE

<table>
<thead>
<tr>
<th>Clinical recommendation</th>
<th>Evidence rating</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use risk stratification based on age and clinical findings to determine whether urine testing is needed in a child with suspected UTI.</td>
<td>C</td>
<td>Disease-oriented outcomes based on cohort studies and evidence-based guidelines</td>
</tr>
<tr>
<td>Do not use perineal bagging to collect urine for cultures because these specimens have high false-positive rates.</td>
<td>C</td>
<td>Disease-oriented outcomes based on evidence-based guidelines</td>
</tr>
<tr>
<td>When clinically possible, use shorter courses of intravenous antibiotics followed by oral antibiotics.</td>
<td>A</td>
<td>Patient-oriented outcomes based on a Cochrane review and cohort study</td>
</tr>
<tr>
<td>Order kidney and bladder ultrasonography for all children younger than 24 months after their first febrile UTI.</td>
<td>C</td>
<td>Guidelines based partly on observational studies</td>
</tr>
<tr>
<td>Order voiding cystourethrogram for children younger than 24 months (or younger than three years, according to one guideline) if they have recurrent UTIs or abnormal ultrasound findings.</td>
<td>C</td>
<td>Guidelines based partly on randomized controlled trials and observational studies</td>
</tr>
<tr>
<td>Use antibiotic prophylaxis selectively to prevent recurrent UTIs; evidence of benefit is small at best, and this practice promotes antimicrobial resistance.</td>
<td>B</td>
<td>Disease- and patient-oriented outcomes based on Cochrane reviews, a systematic review, and a randomized controlled trial</td>
</tr>
<tr>
<td>Evaluate for and treat bowel and bladder dysfunction when UTI is diagnosed to help prevent recurrence.</td>
<td>C</td>
<td>Disease-oriented outcomes based on evidence-based guidelines and a cohort study</td>
</tr>
</tbody>
</table>

UTI = urinary tract infection.
A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to https://www.aafp.org/afpsort.

This article updates previous articles on this topic by White, Alper and Curry, and Hellerstein.

Data Sources: We searched Clinical Queries using various combinations of the key terms urinary tract infection, UTI, children, prevalence, antibiotics, and imaging. We also searched the Cochrane database and the National Guideline Clearinghouse, and used the Essential Evidence summary provided by the AFP editors. Search dates: February 21, 2019; December 12, 2019; and May 8, 2020.

Editor’s Note: In May 2021, the AAP retired its guideline "Urinary Tract Infection: Clinical Practice Guideline for the Diagnosis and Management of the Initial UTI in Febrile Infants and Children 2 to 24 Months," due to its improper use of race as a risk factor. The guideline suggested that "White race" is a risk factor for UTI in girls and "non-Black race" is a risk factor in boys, which ignores the complexities of race and could result in inappropriate underdiagnosis of UTI in Black and non-White children. This article, which was largely based on the AAP guideline, was corrected to remove the text and algorithms that used race as a risk factor for diagnosing UTI in children.—Sumi Sexton, MD, Editor-in-Chief

References


The Authors

BRIAN VEAUTHIER, MD, is the program director of the University of Wyoming Family Medicine Residency Program, Casper.

MICHAEL V. MILLER, DO, is the associate program director of the University of Wyoming Family Medicine Residency Program.

Address correspondence to Brian Veauthier, MD, 1522 E. A St., Casper, WY 82601 (email: bveauthi@uwyo.edu). Reprints are not available from the authors.

References


